THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Amgen's Repatha (evolocumab) has shown benefit in a long-term study in reducing cardiovascular incidents in patients without a prior history of heart attack or stroke. This comes several weeks after ...
The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...
The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy GoodRx (Nasdaq: GDRX), the leading platform for medication ...
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback